Skip to main content

Applied Materials Announces First Quarter 2026 Results

Revenue $7.01 billion, down 2 percent year over year GAAP gross margin 49.0 percent and non-GAAP gross margin 49.1 percent GAAP EPS $2.54 and non-GAAP EPS $2.38, up 75 percent and flat year over year, respectively Semiconductor Systems achieved record DRAM revenue Applied Global Services delivered record services and spares revenueSANTA CLARA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Applied Materials, Inc. (NASDAQ : AMAT) today reported results for its first quarter ended Jan. 25, 2026. First Quarter Results Applied generated revenue of $7.01 billion. On a GAAP basis, the company reported gross margin of 49.0 percent, operating income of $1.83 billion or 26.1 percent of net revenue, and earnings per share (EPS) of $2.54. On a non-GAAP basis, the company reported gross margin of 49.1 percent, operating income of $2.11 billion...

Continue reading

Trisura Group Reports Fourth Quarter and 2025 Annual Results: Robust Growth in BVPS Underscores Disciplined, Profitable Underwriting and Strong Expansion in Investment Income

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced financial results for the fourth quarter and year ended December 31, 2025. David Clare, President and CEO of Trisura, stated, “2025 was characterized by stability, focused growth and consistent execution, with 17.8% growth in book value supported by an 84.9% combined ratio and 17.3% increase in investment income. We ended the year strong, with fourth quarter Operating net income of $36.6 million, or $0.75 per share, contributing to record annual Operating net income of $138.4 million for the year. The strength of our opportunity was highlighted by an 11.8% increase in Net insurance revenue, underpinned by momentum in Primary lines which grew 15.4% in the quarter and 20.4%...

Continue reading

AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business UpdatesTotal revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025. Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments. Net use of cash improved for the second consecutive quarter to approximately $5.1 million, compared to $6.2 million in the third quarter, underscoring continued progress in cash efficiency. Operating expenses...

Continue reading

Alliance Entertainment Reports Second Quarter Fiscal Year 2026 Results

Adjusted EBITDA up 15% to $18.5M; Gross Margin expands 210 basis points to 12.8% Net Income increased to $9.4M, or $0.18 per share, compared to $7.1M, or $0.14 per share, in Q2 FY25 Strengthened balance sheet, ending quarter with $74.1M in working capital PLANTATION, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), a premier distributor, logistics provider, and omnichannel fulfillment partner to the entertainment and pop culture collectibles industry, supplying more than 340,000 unique SKUs across music, video, video games, licensed merchandise, and exclusive collectibles to over 35,000 retail and e-commerce storefronts, reported its financial and operational results for its fiscal second quarter ended December 31, 2025. Second Quarter FY 2026 HighlightsSustained Profitability...

Continue reading

2025 Annual Results

  Solid growth, Improved margins Acceleration ConfirmedSales: 44.05 billion euros, +4.0% like-for-like1 and +1.3% reported. Another year of outperformance in an improving beauty market. Growth1 in all Divisions, led by Professional Products. Growth1 in all regions witha broad-based acceleration in the second half. E-commerce2 growing double digits passing the 30% mark. Gross margin up +10 basis points at 74.3%. Operating margin up +20 basis points at 20.2%. Earnings per share3 12.71 euros, up +0.4%. Dividend per share4 7.20 euros, up +2.9%. Net cash flow: 7.2 billion euros, up +7.8%. Sustainability leader: The only company in the world to be awarded a triple ‘A’ rating by CDP for ten years in a row. Ranked in the global top 1% for environmental and social performance by EcoVadis.Commenting on the figures, Nicolas Hieronimus, CEO of...

Continue reading

Seanergy Maritime Announces the Date for the Fourth Quarter and Year Ended December 31, 2025, Financial Results, Conference Call and Webcast

Earnings Release: Tuesday, February 17, 2026, Before Market Open in New York Conference Call and Webcast: Tuesday, February 17, 2026, at 10:00 a.m. Eastern Time GLYFADA, Greece, Feb. 12, 2026 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today that it will release its financial results for the fourth quarter and year ended December 31, 2025, prior to the open of the market in New York on Tuesday, February 17, 2026. Seanergy’s senior management will conduct a conference call and simultaneous Internet webcast to review these results on Tuesday, February 17, 2026, at 10:00 a.m. Eastern Time. Audio Webcast and Earnings Presentation:There will be a live, and then archived, webcast of the conference call and accompanying slides available through the Company’s website. To access...

Continue reading

Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal second quarter...

Continue reading

Live Ventures Reports Fiscal First Quarter 2026 Financial Results

LAS VEGAS, Feb. 12, 2026 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal first quarter ended December 31, 2025.  Fiscal First Quarter 2026 Key Highlights:Revenue was $108.5 million, compared to $111.5 million in the prior-year period Gross margin increased to 32.6%, compared to 31.7% in the prior-year period Operating income increased $2.7 million, or 352.9%, to $3.5 million, compared to $0.8 million in the prior-year period Net loss was $0.1 million and diluted loss per share was $0.02, compared to net income of $0.5 million and diluted earnings per share (“EPS”) of $0.16 in the prior-year period. Net income for the prior-year period includes a net gain of $3.6 million from non-recurring items Adjusted...

Continue reading

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

–The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint- – An update on the Interim clinical results for Cohort 2 is planned for mid-2026- -FDA meeting to formalize the pivotal BB-301 study design expected mid-year- HAYWARD, Calif.,, Feb. 12, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma...

Continue reading

Freddie Mac Announces Fourth Quarter and Full-Year 2025 Financial Results

MCLEAN, Va., Feb. 12, 2026 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today reported its Fourth Quarter and Full-Year 2025 financial results and filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission. The company’s Form 10-K and earnings press release, along with the Fourth Quarter 2025 financial results supplement are available now on the Investor Relations page of the company’s website. The company will hold a call at 9 a.m. Eastern Time (ET) today, February 12, 2026, to share its results with the media. The call will be concurrently webcast, and the replay will be available on the company’s website for approximately 30 days. Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability, and affordability in the housing market throughout all economic...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.